Medicine and Dentistry
Breast Cancer
100%
Patient
93%
Therapeutic Procedure
41%
Diseases
25%
Woman
25%
Malignant Neoplasm
25%
Combination Therapy
24%
Hormone Therapy
21%
Gene
21%
Neoplasm
21%
Triple Negative Breast Cancer
16%
Metastatic Breast Cancer
16%
Association
15%
Recurrent Disease
15%
Inpatient
13%
Single Nucleotide Polymorphism
12%
Age
11%
Estrogen Receptor
11%
BRCA1
11%
Trastuzumab
10%
Adiponectin
10%
Tamoxifen
10%
Predictor
9%
Toxicity
8%
Capecitabine
8%
Paclitaxel
8%
Assessment
8%
Serum
8%
Leptin
8%
Hormone Receptor
8%
Eribulin
8%
Development
7%
Diagnosis
7%
Progression Free Survival
7%
Overall Survival
7%
Transforming Growth Factor
7%
Gamma Urogastrone
7%
Odds Ratio
7%
Breast
6%
BRCA2
6%
Receptor
6%
Homologous Recombination
6%
Prostate Cancer
5%
Biological Marker
5%
Epidermal Growth Factor Receptor 2
5%
Survival
5%
Lapatinib
5%
Cancer Cell
5%
Solid Malignant Neoplasm
5%
Carboplatin
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
93%
Malignant Neoplasm
21%
Diseases
19%
Neoplasm
19%
Cancer Risk
16%
Metastatic Breast Cancer
15%
Recurrent Disease
15%
Clinical Trial
14%
Triple Negative Breast Cancer
12%
Leptin
11%
Adiponectin
10%
Tamoxifen
9%
Toxicity
9%
Trastuzumab
9%
Capecitabine
8%
Paclitaxel
8%
Hormone Receptor
8%
Eribulin
8%
Overall Survival
7%
Gamma Urogastrone
7%
Progression Free Survival
7%
Colorectal Cancer
6%
Epidermal Growth Factor Receptor 2
6%
Prostate Cancer
5%
Biological Marker
5%
Chemotherapy
5%
Receptor
5%
Lapatinib
5%
Solid Malignant Neoplasm
5%
Anthracycline
5%
Carboplatin
5%
Transforming Growth Factor
5%
Survival
5%
Sorafenib
5%
Metastasis
5%
Biochemistry, Genetics and Molecular Biology
Nested Gene
17%
Association
15%
Adiponectin
13%
Estrogen Receptor
12%
Mutation
11%
BRCA1
10%
Age
10%
Single-Nucleotide Polymorphism
9%
Clinical Trial
8%
Leptin
7%
Development
7%
Overall Survival
7%
Growth
6%
Hormone Receptor
6%
Homologous Recombination
6%
BRCA2
5%
Progression Free Survival
5%
Solid
5%
Cancer Cell
5%
